You are here

  • Home
  • Online First
  • Effects of prophylactic hydrocortisone in a tertiary Canadian NICU

Article Text

Article menu
Download PDFPDF
Letter
Effects of prophylactic hydrocortisone in a tertiary Canadian NICU
  1. Marisa de Souza1,
  2. Raymond Melika2,
  3. Bernard Thebaud3,4,5,6,
  4. Nicholas James Barrowman5,6,
  5. Anne Tsampalieros5,
  6. Brigitte Lemyre3,4,5,6
  1. 1Pediatrics, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada
  2. 2Pharmacy, Ottawa Hospital General Campus, Ottawa, Ontario, Canada
  3. 3Neonatology, Ottawa Hospital, Ottawa, Ontario, Canada
  4. 4Neonatology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
  5. 5Clinical Research Unit, CHEO Research Institute, Ottawa, Ontario, Canada
  6. 6Pediatrics, University of Ottawa, Ottawa, Ontario, Canada
  1. Correspondence to Dr Marisa de Souza, Pediatrics, Northern Ontario School of Medicine, Thunder Bay, ON P3E 2C6, Canada; mdesouza{at}cheo.on.ca

http://dx.doi.org/10.1136/archdischild-2023-325913

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Bronchopulmonary dysplasia (BPD) is a common complication of preterm birth. Recent evidence suggests that the use of physiological doses of hydrocortisone for the prevention of death or BPD may outweigh the potential risks.1–3 Starting in 2019, all infants born <28 weeks gestational age (GA) in our tertiary care NICU received physiologic doses of hydrocortisone, starting within 24 hours post-birth. Our objective was to determine the effect of prophylactic hydrocortisone on the incidence of survival without moderate or severe BPD; secondary objectives assessed duration of respiratory support and safety outcomes.

    We performed a single-centre retrospective cohort study of infants born <28 weeks GA during two epochs, before (16 months) and after (19 months) the implementation of prophylactic hydrocortisone. The primary objective was evaluated …

    View Full Text

    Footnotes

    • Presented at This data was presented at the 2022 Canadian Paediatric Society Conference.4

    • Contributors MdS assisted with the design of the study, collected the data, drafted and revised the manuscript. RM collected the data, drafted and revised the manuscript. AT and NJB analysed the data, created figures and tables and edited the manuscript. BT advised in the study design and revised the manuscript. BL designed the study and revised the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.